See more : BlackWall Limited (BWF.AX) Income Statement Analysis – Financial Results
Complete financial analysis of BioPorto A/S (THOXF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of BioPorto A/S, a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
You may be interested
- NeoDynamics AB (publ) (NEOD.ST) Income Statement Analysis – Financial Results
- Dacian Gold Limited (DCN.AX) Income Statement Analysis – Financial Results
- Nova Minerals Limited (NVA) Income Statement Analysis – Financial Results
- PharmaCom BioVet, Inc. (PHMB) Income Statement Analysis – Financial Results
- Dynavolt Renewable Energy Technology (Henan) Co., Ltd. (002684.SZ) Income Statement Analysis – Financial Results
BioPorto A/S (THOXF)
About BioPorto A/S
BioPorto A/S, an in-vitro diagnostics company, provides diagnostic tests and antibodies to clinicians and researchers worldwide. The company offers the neutrophil gelatinase-associated lipocalin test, a particle-enhanced turbidimetric test that measures NGAL that is used to supplement clinical evaluation and standard tests; monoclonal antibodies for scientific, pharmaceutical, and clinical research use; enzyme-linked immunosorbent assay kits; IVD automated assays; and generic rapid assay device platform for the development of lateral flow assays. It sells its products through own sales team, distributors, and OEM partnerships. The company was founded in 2000 and is headquartered in Hellerup, Denmark.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 30.96M | 28.97M | 24.25M | 23.20M | 26.62M | 26.02M | 25.16M | 20.72M | 20.38M | 18.71M | 16.63M | 17.86M | 18.58M | 13.80M | 11.01M | 8.34M | 8.34M | 5.55M | 4.36M |
| Cost of Revenue | 10.78M | 9.93M | 9.21M | 9.87M | 9.29M | 8.18M | 6.91M | 5.03M | 4.90M | 5.51M | 7.58M | 6.80M | 8.06M | 5.34M | 4.75M | 4.62M | 4.62M | 2.42M | 4.49M |
| Gross Profit | 20.18M | 19.04M | 15.04M | 13.34M | 17.33M | 17.84M | 18.25M | 15.69M | 15.48M | 13.20M | 9.04M | 11.06M | 10.52M | 8.46M | 6.26M | 3.72M | 3.72M | 3.13M | -123.00K |
| Gross Profit Ratio | 65.19% | 65.73% | 62.01% | 57.49% | 65.09% | 68.55% | 72.54% | 75.74% | 75.95% | 70.55% | 54.39% | 61.91% | 56.61% | 61.28% | 56.85% | 44.58% | 44.58% | 56.43% | -2.82% |
| Research & Development | 25.45M | 34.94M | 30.26M | 28.13M | 24.56M | 18.68M | 21.93M | 9.67M | 9.94M | 8.62M | 10.21M | 9.91M | 8.13M | 8.90M | 8.64M | 6.38M | 6.38M | 7.64M | 6.68M |
| General & Administrative | 36.03M | 41.83M | 32.66M | 28.02M | 27.80M | 20.01M | 14.27M | 13.03M | 9.42M | 10.44M | 12.67M | 9.04M | 8.79M | 8.26M | 7.97M | 7.48M | 7.48M | 7.89M | 5.32M |
| Selling & Marketing | 18.87M | 21.22M | 17.38M | 20.79M | 39.27M | 20.94M | 18.55M | 18.04M | 8.88M | 9.40M | 5.97M | 5.97M | 6.46M | 4.71M | 5.67M | 3.90M | 3.90M | 2.26M | 2.23M |
| SG&A | 54.90M | 63.05M | 50.04M | 48.80M | 67.07M | 40.94M | 32.81M | 31.07M | 18.30M | 19.84M | 18.63M | 15.01M | 15.25M | 12.97M | 13.63M | 11.38M | 11.38M | 10.15M | 7.55M |
| Other Expenses | 1.01M | 274.00K | -548.00K | -474.00K | -591.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 81.35M | 97.99M | 80.30M | 76.93M | 91.63M | 59.62M | 54.74M | 40.74M | 28.24M | 28.45M | 28.85M | 24.92M | 23.38M | 21.87M | 22.28M | 17.76M | 16.78M | -11.53M | -14.48M |
| Cost & Expenses | 92.13M | 107.91M | 89.51M | 86.79M | 100.92M | 67.80M | 61.65M | 45.77M | 33.14M | 33.96M | 36.43M | 31.73M | 31.44M | 27.21M | 27.03M | 22.39M | 21.40M | -9.11M | -9.99M |
| Interest Income | 1.04M | 44.00K | 0.00 | 4.00K | 75.00K | 27.00K | 25.00K | 64.00K | 93.00K | 210.00K | 56.00K | -273.00K | 68.00K | 93.00K | 124.00K | 1.75M | 763.00K | 1.26M | 755.00K |
| Interest Expense | 571.00K | 1.09M | 912.00K | 780.00K | 326.00K | 38.00K | 31.00K | 29.00K | 279.00K | 15.00K | 1.68M | 1.82M | 2.05M | 889.00K | 61.00K | 125.00K | 982.00K | 190.00K | 153.00K |
| Depreciation & Amortization | 2.68M | 3.97M | 4.33M | 3.99M | 2.86M | 543.00K | 504.00K | 390.00K | 300.00K | 270.00K | 107.00K | 189.00K | 8.00K | 325.00K | 345.00K | 384.00K | 395.00K | 442.00K | 460.00K |
| EBITDA | -57.96M | -77.81M | -58.60M | -62.06M | -71.06M | -41.04M | -36.53M | -24.48M | -12.44M | -14.81M | -20.09M | -13.94M | -12.88M | -12.99M | -15.55M | -14.23M | -12.67M | -12.96M | 15.57M |
| EBITDA Ratio | -187.21% | -255.13% | -241.61% | -267.45% | -266.94% | -157.73% | -145.22% | -118.15% | -61.01% | -79.18% | -120.85% | -78.08% | -68.78% | -94.14% | -141.24% | -163.80% | -151.89% | 294.54% | 356.95% |
| Operating Income | -61.17M | -77.88M | -65.26M | -63.59M | -74.30M | -41.78M | -36.49M | -25.05M | -12.76M | -15.26M | -19.80M | -13.87M | -12.86M | -13.41M | -16.02M | -14.05M | -14.05M | 14.66M | 14.36M |
| Operating Income Ratio | -197.60% | -268.83% | -269.05% | -274.05% | -279.09% | -160.60% | -145.08% | -120.88% | -62.60% | -81.56% | -119.11% | -77.67% | -69.19% | -97.17% | -145.50% | -168.41% | -168.41% | 263.94% | 329.09% |
| Total Other Income/Expenses | -35.00K | -2.60M | 1.42M | -3.24M | 52.00K | 164.00K | -570.00K | 148.00K | -255.00K | 159.00K | -2.07M | -2.08M | -1.98M | -796.00K | 63.00K | -697.00K | -219.00K | 30.39M | 602.00K |
| Income Before Tax | -61.21M | -81.55M | -63.84M | -66.83M | -74.25M | -41.62M | -37.06M | -24.90M | -13.01M | -15.10M | -21.87M | -15.95M | -14.84M | -14.21M | -15.95M | -14.26M | -14.26M | 15.73M | 14.96M |
| Income Before Tax Ratio | -197.71% | -281.50% | -263.21% | -288.03% | -278.89% | -159.97% | -147.34% | -120.17% | -63.85% | -80.71% | -131.57% | -89.32% | -79.84% | -102.93% | -144.93% | -171.03% | -171.03% | 283.17% | 342.89% |
| Income Tax Expense | -4.88M | -5.62M | -6.73M | -5.27M | -4.61M | -3.57M | -4.82M | -2.10M | -2.28M | -2.17M | -1.25M | -1.25M | 68.00K | 93.00K | 124.00K | 0.00 | 982.00K | 32.71M | 30.67M |
| Net Income | -56.33M | -75.92M | -57.11M | -61.56M | -69.64M | -38.05M | -32.24M | -22.80M | -10.73M | -12.93M | -20.62M | -14.70M | -14.84M | -14.21M | -15.95M | -14.26M | -14.26M | -15.73M | -14.96M |
| Net Income Ratio | -181.95% | -262.08% | -235.48% | -265.31% | -261.60% | -146.25% | -128.18% | -110.04% | -52.65% | -69.10% | -124.05% | -82.32% | -79.84% | -102.93% | -144.93% | -171.03% | -171.03% | -283.17% | -342.89% |
| EPS | -0.16 | -0.23 | -0.21 | -0.29 | -0.27 | -0.19 | -0.18 | -0.14 | -0.07 | -0.09 | -0.21 | -0.19 | -0.21 | -0.20 | -0.24 | -0.22 | -0.27 | -0.39 | -0.39 |
| EPS Diluted | -0.16 | -0.23 | -0.21 | -0.29 | -0.27 | -0.19 | -0.18 | -0.14 | -0.07 | -0.09 | -0.21 | -0.19 | -0.21 | -0.20 | -0.24 | -0.22 | -0.27 | -0.39 | -0.39 |
| Weighted Avg Shares Out | 358.50M | 331.20M | 278.05M | 213.54M | 255.47M | 197.25M | 182.02M | 164.97M | 153.17M | 148.41M | 99.65M | 75.54M | 71.83M | 70.27M | 65.45M | 63.86M | 52.57M | 40.62M | 38.41M |
| Weighted Avg Shares Out (Dil) | 358.50M | 331.20M | 278.05M | 213.54M | 255.47M | 197.25M | 182.02M | 164.97M | 153.17M | 148.41M | 99.65M | 75.54M | 71.83M | 70.27M | 65.45M | 63.86M | 52.57M | 40.62M | 38.41M |
BioPorto A/S to Host First Quarter 2024 Earnings Webcast and Investor Meeting
May 2, 2024 News release BioPorto A/S to Host First Quarter 2024 Earnings Webcast and Investor Meeting COPENHAGEN, DENMARK and BOSTON, MA, USA, May 2, 2024 (GLOBE NEWSWIRE) – BioPorto A/S (BioPorto or the Company) (CPH:BIOPOR), an in vitro diagnostics...
BioPorto A/S Appoints Chief Legal Officer
April 10, 2024 Announcement no. 8 BioPorto A/S Appoints Chief Legal Officer COPENHAGEN, DENMARK and BOSTON, MA, USA, April 10, 2024, (GLOBE NEWSWIRE) -- BioPorto A/S (BioPorto or Company) (CPH:BIOPOR), an in vitro diagnostics company focused on empowering the early detection...
Notice convening the Annual General Meeting in BioPorto A/S
April 4, 2024 Announcement no. 6 Notice convening the Annual General Meeting in BioPorto A/S The Board of Directors hereby convenes the Annual General Meeting of BioPorto A/S (“BioPorto” or the “Company”) to be held on: Tuesday April 30, 2024,...
Correction: BioPorto Announces Annual Results for 2023
Correction: Updated Annual Report attached April 4, 2024 Announcement no. 05 BioPorto Announces Annual Results for 2023 COPENHAGEN, DENMARK and BOSTON, MA, USA, April 4, 2024, (GLOBE NEWSWIRE) -- BioPorto A/S (BioPorto or Company) (CPH:BIOPOR), an in vitro diagnostics company focused on empowering the...
BioPorto Announces Annual Results for 2023
April 4, 2024 Announcement no. 05 BioPorto Announces Annual Results for 2023 COPENHAGEN, DENMARK and BOSTON, MA, USA, April 4, 2024, (GLOBE NEWSWIRE) -- BioPorto A/S (BioPorto or Company) (CPH:BIOPOR), an in vitro diagnostics company focused on empowering the early detection of Acute...
BioPorto appoints Peter Mørch Eriksen as permanent Group Chief Executive Officer
April 2, 2024 Announcement no. 04 BioPorto appoints Peter Mørch Eriksen as permanent Group Chief Executive Officer COPENHAGEN, DENMARK and BOSTON, MA, USA, April 2, 2024, (GLOBE NEWSWIRE) -- BioPorto A/S (BioPorto or Company) (CPH:BIOPOR), an in vitro diagnostics company focused...
BioPorto announces preliminary results for 2023 and provides strategic update for the period 2024-2026
February 22, 2024 Announcement no. 03 BioPorto announces preliminary results for 2023 and provides strategic update for the period 2024-2026 COPENHAGEN, DENMARK and BOSTON, MA, February 22, 2024, (GLOBE NEWSWIRE) – BioPorto A/S (BioPorto or the Company) (CPH:BIOPOR), today announced its...
Roche Diagnostics and BioPorto expand collaboration
20 February 20, 2024 Announcement no. 02 Roche Diagnostics and BioPorto expand collaboration COPENHAGEN, DENMARK and BOSTON, MA, 20 February, 2024, (GLOBE NEWSWIRE) – BioPorto A/S (BioPorto or the Company) (CPH:BIOPOR), has today announced an expansion of its strategic collaboration...
BioPorto A/S to host investor meetings on 22 February 2024
19 February 2024 News Release BioPorto A/S to host investor meetings on 22 February 2024 COPENHAGEN, DENMARK and BOSTON, Mass., 19 February 2024, BioPorto A/S (BioPorto or Company), an in vitro diagnostics company focused on empowering the early detection of...
BioPorto implements changes to the Executive Management.
January 9, 2024 Announcement no. 01 BioPorto implements changes to the Executive Management.
Source: https://incomestatements.info
Category: Stock Reports